Rafferty Asset Management LLC Acquires 42,948 Shares of Oric Pharmaceuticals, Inc. $ORIC

Rafferty Asset Management LLC raised its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 100.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 85,592 shares of the company’s stock after buying an additional 42,948 shares during the period. Rafferty Asset Management LLC owned about 0.09% of Oric Pharmaceuticals worth $1,027,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. AQR Capital Management LLC bought a new stake in shares of Oric Pharmaceuticals during the 1st quarter valued at $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock worth $226,000 after purchasing an additional 3,131 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Oric Pharmaceuticals by 9.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock worth $1,645,000 after purchasing an additional 24,778 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Oric Pharmaceuticals by 1,331.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock worth $2,841,000 after purchasing an additional 473,600 shares during the period. Finally, Jane Street Group LLC lifted its position in Oric Pharmaceuticals by 56.0% during the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock valued at $174,000 after purchasing an additional 11,198 shares in the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Insider Buying and Selling at Oric Pharmaceuticals

In other news, CEO Jacob Chacko sold 33,374 shares of Oric Pharmaceuticals stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $302,368.44. Following the sale, the chief executive officer owned 581,711 shares in the company, valued at $5,270,301.66. This trade represents a 5.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Dominic Piscitelli sold 52,000 shares of the business’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at $920,679.48. This trade represents a 43.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 106,814 shares of company stock valued at $1,199,135 in the last three months. 6.82% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on ORIC. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research report on Tuesday, February 24th. JPMorgan Chase & Co. boosted their price objective on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Evercore started coverage on shares of Oric Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $25.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.20.

Oric Pharmaceuticals Stock Down 1.0%

Shares of Oric Pharmaceuticals stock opened at $13.71 on Friday. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -9.02 and a beta of 1.28. The stock’s 50-day simple moving average is $10.92 and its 200-day simple moving average is $11.14. Oric Pharmaceuticals, Inc. has a 52 week low of $3.90 and a 52 week high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.04. On average, equities analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.